MX2021012098A - Oligonucleotidos antisentido del transcrito tipo 2 de angiopoyetina (angptl2) y sus usos. - Google Patents
Oligonucleotidos antisentido del transcrito tipo 2 de angiopoyetina (angptl2) y sus usos.Info
- Publication number
- MX2021012098A MX2021012098A MX2021012098A MX2021012098A MX2021012098A MX 2021012098 A MX2021012098 A MX 2021012098A MX 2021012098 A MX2021012098 A MX 2021012098A MX 2021012098 A MX2021012098 A MX 2021012098A MX 2021012098 A MX2021012098 A MX 2021012098A
- Authority
- MX
- Mexico
- Prior art keywords
- angptl2
- antisense oligonucleotides
- expression
- disorders
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
Abstract
La presente invención se refiere a oligonucleótidos antisentido, que se dirigen al ARNm de ANGPTL2 en una célula, lo que conduce a una expresión reducida de la proteína ANGPTL2. La reducción de la expresión de la proteína NGPTL2 es beneficiosa para el tratamiento de ciertos trastornos médicos, tales como los asociados con la expresión y/o actividad anormal de ANGPTL2, por ejemplo, enfermedades o trastornos relacionados con el sistema cardiovascular.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962828864P | 2019-04-03 | 2019-04-03 | |
PCT/US2020/026379 WO2020206115A2 (en) | 2019-04-03 | 2020-04-02 | Angptl2 antisense oligonucleotides and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021012098A true MX2021012098A (es) | 2021-11-03 |
Family
ID=70465458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021012098A MX2021012098A (es) | 2019-04-03 | 2020-04-02 | Oligonucleotidos antisentido del transcrito tipo 2 de angiopoyetina (angptl2) y sus usos. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220213484A1 (es) |
EP (1) | EP3947680A2 (es) |
JP (1) | JP2022524218A (es) |
KR (1) | KR20210149107A (es) |
CN (1) | CN113906139A (es) |
AU (1) | AU2020252374A1 (es) |
BR (1) | BR112021019182A2 (es) |
CA (1) | CA3135794A1 (es) |
EA (1) | EA202192733A1 (es) |
IL (1) | IL286826A (es) |
MX (1) | MX2021012098A (es) |
SG (1) | SG11202110745VA (es) |
WO (1) | WO2020206115A2 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3131970B1 (fr) | 2022-01-14 | 2024-02-23 | Univ D’Aix Marseille Amu | Dispositif pour la simulation en chirurgie abdominale |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
EP0724447B1 (en) | 1991-10-24 | 2003-05-07 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
AU9063398A (en) | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
JPH11341989A (ja) * | 1998-03-31 | 1999-12-14 | Sanyo Electric Co Ltd | Dna断片増幅方法、dna断片増幅装置、微生物群測定方法、微生物群分析方法および汚染物質測定方法 |
NZ513402A (en) | 1999-02-12 | 2003-06-30 | Sankyo Co | Novel nucleosides and oligonucleotide analogues |
CN102180924A (zh) | 1999-05-04 | 2011-09-14 | 桑塔里斯制药公司 | L-核糖-lna类似物 |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
ES2607471T3 (es) | 2002-11-18 | 2017-03-31 | Roche Innovation Center Copenhagen A/S | Diseño antisentido |
WO2004083430A2 (en) | 2003-03-21 | 2004-09-30 | Santaris Pharma A/S | SHORT INTERFERING RNA (siRNA) ANALOGUES |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
DK1984382T3 (da) | 2006-01-27 | 2012-09-03 | Santaris Pharma As | LNA modificerede fosforthiolerede oligonukleotider |
ES2516815T3 (es) | 2006-01-27 | 2014-10-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en la posición 6 |
DK2002004T3 (en) | 2006-03-23 | 2015-11-30 | Roche Innovation Ct Copenhagen As | LITTLE INTERNAL SEGMENTED INTERFERENCE RNA |
AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
AU2008260277C1 (en) | 2007-05-30 | 2014-04-17 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
CN101796062B (zh) | 2007-07-05 | 2014-07-30 | Isis制药公司 | 6-双取代双环核酸类似物 |
US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
EP2356129B1 (en) | 2008-09-24 | 2013-04-03 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
EP2403946A4 (en) * | 2009-03-04 | 2012-11-14 | TREATMENT OF SIRTUIN 1 (SIRT1) -HANDLED ILLNESSES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST SIRT 1 | |
US9012421B2 (en) | 2009-08-06 | 2015-04-21 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
US9364495B2 (en) | 2009-10-20 | 2016-06-14 | Roche Innovation Center Copenhagen A/S | Oral delivery of therapeutically effective LNA oligonucleotides |
EP2580228B1 (en) | 2010-06-08 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
WO2013033230A1 (en) | 2011-08-29 | 2013-03-07 | Isis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
WO2013154798A1 (en) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
MX363068B (es) | 2012-11-15 | 2019-03-07 | Roche Innovation Ct Copenhagen As | Conjugados de oligonucleotido. |
WO2014167529A1 (en) * | 2013-04-10 | 2014-10-16 | Institut De Cardiologie De Montreal | Methods and compositions for preventing and treating atherosclerosis |
PL2992009T3 (pl) | 2013-05-01 | 2020-11-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji apolipoproteiny(a) |
PE20160158A1 (es) | 2013-06-27 | 2016-03-18 | Roche Innovation Ct Copenhagen As | Oligomeros antisentido y conjugados con diana en pcsk9 |
MX2017010066A (es) * | 2015-02-04 | 2017-11-01 | Hoffmann La Roche | Oligomeros antisentido de tau y usos de los mismos. |
US11504391B1 (en) | 2016-11-23 | 2022-11-22 | Alnylam Pharmaceuticals, Inc. | Modified RNA agents with reduced off-target effect |
-
2020
- 2020-04-02 KR KR1020217035359A patent/KR20210149107A/ko unknown
- 2020-04-02 EA EA202192733A patent/EA202192733A1/ru unknown
- 2020-04-02 CA CA3135794A patent/CA3135794A1/en active Pending
- 2020-04-02 JP JP2021559064A patent/JP2022524218A/ja active Pending
- 2020-04-02 AU AU2020252374A patent/AU2020252374A1/en active Pending
- 2020-04-02 WO PCT/US2020/026379 patent/WO2020206115A2/en unknown
- 2020-04-02 CN CN202080039696.2A patent/CN113906139A/zh active Pending
- 2020-04-02 MX MX2021012098A patent/MX2021012098A/es unknown
- 2020-04-02 US US17/594,154 patent/US20220213484A1/en active Pending
- 2020-04-02 SG SG11202110745VA patent/SG11202110745VA/en unknown
- 2020-04-02 BR BR112021019182A patent/BR112021019182A2/pt unknown
- 2020-04-02 EP EP20722089.8A patent/EP3947680A2/en active Pending
-
2021
- 2021-09-29 IL IL286826A patent/IL286826A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021019182A2 (pt) | 2022-05-31 |
KR20210149107A (ko) | 2021-12-08 |
WO2020206115A2 (en) | 2020-10-08 |
WO2020206115A3 (en) | 2020-11-12 |
EA202192733A1 (ru) | 2022-03-14 |
CA3135794A1 (en) | 2020-10-08 |
CN113906139A (zh) | 2022-01-07 |
US20220213484A1 (en) | 2022-07-07 |
SG11202110745VA (en) | 2021-10-28 |
AU2020252374A1 (en) | 2021-11-11 |
EP3947680A2 (en) | 2022-02-09 |
JP2022524218A (ja) | 2022-04-28 |
IL286826A (en) | 2021-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020008581A (es) | Oligonucleotidos antisentido de la proteina cinasa del tipo ii delta dependiente del calcio/calmodulina (camk2d) y sus usos. | |
WO2016176690A3 (en) | Gene therapy for autosomal dominant diseases | |
CR20210415A (es) | Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidoria en cdk2 | |
PH12017550069A1 (en) | Tau antisense oligomers and uses thereof | |
MX2021012126A (es) | Composiciones y métodos para inhibir la expresión génica en el sistema nervioso central. | |
PH12020500570A1 (en) | Alpha-synuclein antisense oligonucleotides and uses thereof | |
MY180626A (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
MX2016013832A (es) | Composiciones y metodos para tratar hemoglobinopatias. | |
MX2022016415A (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. | |
MX2019015741A (es) | Tratamiento con plasminogeno de afecciones asociadas a la sobreexpresion de pai-1. | |
MX2023001450A (es) | Composiciones y metodos para la inhibicion de la expresion de plp1. | |
WO2011082409A3 (en) | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 | |
MX2020007439A (es) | Oligonucleotidos antisentido que actuan sobre alfa-sinucleina y usos de estos. | |
EP4279127A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
GB201202561D0 (en) | Treatment of skin disorders | |
MX2018012695A (es) | Oligomeros antisentido y metodos de uso de los mismos para tratar enfermedades relacionadas con el gen alpha-glucosidasa acido. | |
EP2563794A4 (en) | INHIBITORS OF TYROSINE KINASE PROTEIN ACTIVITY AND THEIR APPLICATIONS TO THE TREATMENT OF OPHTHALMIC DISORDERS | |
MX2020007433A (es) | Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos. | |
WO2017011356A3 (en) | Mcj inhibitors for use in treating drug-induced diseases and conditions | |
MX2021012098A (es) | Oligonucleotidos antisentido del transcrito tipo 2 de angiopoyetina (angptl2) y sus usos. | |
PH12019502388A1 (en) | Prevention and/or treatment of inflammatory skin disease | |
WO2023081500A3 (en) | RNAi OLIGONUCLEOTIDE CONJUGATES | |
WO2019055776A3 (en) | Compositions and methods for treatment of diseases involving cxcl1 function | |
GB201314859D0 (en) | Molecular targets for healing or treating wounds | |
MX2021011301A (es) | Terapia combinada especifica contra tumores. |